SCHEMBL198192

SCHEMBL198192

Clc1ccc(Cl)c2nccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.43
MAPT P10636 6/20 0.43
LMNA P02545 5/20 0.43
HSP90AA1 P07900 4/20 0.43
METAP2 P50579 2/20 0.43
METAP1 P53582 2/20 0.43
NR4A2 P43354 1/20 0.43
BRD4 O60885 1/20 0.43
CCR1 P32246 2/20 0.38
CCR8 P51685 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 6/20 0.37
TDP1 Q9NUW8 6/20 0.37
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
CYP3A4 P08684 4/20 0.37
TP53 P04637 3/20 0.37
ALOX15 P16050 3/20 0.37
HTT P42858 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014902 0.87 NR4A2 (0.48) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL13313294 0.84 KDM4E (0.59) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL21800374 0.84 MAPK1 (0.35) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL5185445 0.84 KDM4E (0.35) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL29310018 0.79 KDM4E (0.36) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL18980547 0.79 LRRK2 (0.40) NR4A2L3MBTL1ALDH1A1TDP1
SCHEMBL740008 0.79 NR4A2 (0.36) KDM4EMAPTLMNAHSP90AA1METAP2
SCHEMBL21081333 0.78 CCNB2 (0.41) KDM4EMAPTLMNAALDH1A1TDP1
SCHEMBL18980061 0.78 KDM4C (0.49) KDM4EMAPTLMNAL3MBTL1ALDH1A1
SCHEMBL15397154 0.77 NR4A2 (0.42) KDM4EMAPTLMNAHSP90AA1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947213-B1 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2021-03-16 US disclosed
US-10696649-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2020-06-30 US disclosed
US-20200095222-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2020-03-26 US disclosed
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-8088883-B2 Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED 2011-02-24 US disclosed
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2010-11-18 US disclosed
EP-2233459-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-09-29 EP disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed
EP-2192124-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-06-02 EP disclosed
EP-2172470-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-04-07 EP disclosed
US-20090326188-A1 Method for producing polyarylene SUMITOMO CHEMICAL COMPANY, LIMITED 2009-12-31 US disclosed
EP-2065420-A1 METHOD FOR PRODUCING POLYARYLENE Sumitomo Chemical Company, Limited (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP1M1 KDM4E 1741/4885MAPT 783/4885LMNA 2664/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 KDM4E 2705/4885MAPT 1124/4885LMNA 3345/4885
US-10947213-B1 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KDM4E 1863/4885MAPT 4219/4885LMNA 1762/4885
US-20200095222-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KDM4E 1863/4885MAPT 4219/4885LMNA 1762/4885
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND TYR, PAH, AHR KDM4E 524/4885MAPT 491/4885LMNA 2021/4885
US-10696649-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KDM4E 1863/4885MAPT 4219/4885LMNA 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.